A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

  • End date
    Jun 30, 2024
  • participants needed
  • sponsor
    Zhengzhou University
Updated on 19 August 2021


To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy of T cell lymphoma and NK/T cell lymphoma-associated hemophagocytic syndrome.


This is an open, one-arm, prospective clinical collaborative study. This study is aimed to observe the efficacy and safety of the new combined therapy of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy patients with primary central nervous system lymphoma. A total of 30 patients plan to participate in the study. The primary endpoint is objective remission rate (ORR) of hemophagocytic syndrome, and the secondary endpoints include progression-free survival (PFS) , objective remission rate (ORR) of lymphoma, overall survival (OS), and adverse events(ADR).

Condition Angiocentric T-cell lymphoma, Hemophagocytic lymphohistiocytosis
Treatment Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
Clinical Study IdentifierNCT04999878
SponsorZhengzhou University
Last Modified on19 August 2021


Yes No Not Sure

Inclusion Criteria

Histopathologically proven T-cell lymphoma or NK/ T-cell lymphoma
Comply with HLH-2004 diagnostic criteria;Hemophagocytic syndrome can be diagnosed when either of the following two criteria is met
Molecular diagnosis is consistent with hemophagocytic syndrome. Pathological mutations were found in known pathogenic genes related to hemophagocytic syndrome, such as PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST, SH2D1A, BIRC4, ITK, AP3B1, MAGT1, CD27, etc
Meet 5 of the following 8 indicators I. Fever: The body temperature was > 38.5, lasting > for 7 days. II. Splenomegaly . III. Hemocytopenia (involving two or three lines of peripheral blood) : hemoglobin < 90g/L, platelet < 10010^9/L, neutrophils < 1.010^9/L and not caused by reduced hematopoietic function of bone marrow
IV. Hypertriglyceridemia and/or hypofibrinogenemia: triglyceride > 3mmol/L or
standard deviations higher than the same age, fibrinogen < 1.5g/L or 3
standard deviations lower than the same age
V. Hemophagocytes are found in bone marrow, spleen, liver, or lymph nodes
VI.NK cell activity decreased or absent. VII. Elevated serum ferritin
ferritin 500g/L. VIII. Elevated sCD25 (soluble interleukin-2 receptor)
\. Ages 14-75 years
\. Expected survival of more than 1 week
\. Patients with left ventricular ejection fraction > 50%, no major bleeding
of active internal organs (digestive tract, lung, brain, etc.), and
oxygenation index > 250\
\. Patients have good compliance with the planned treatment and follow-up
can understand the research process of this study and sign the written
informed consent

Exclusion Criteria

Three or more drugs including ruxolitinb, etoposide, pemasparase, gemcitabine or cisplatin were used simultaneously in the previous 28 days
Pregnant or lactating women and patients of reproductive age who refuse to take appropriate contraceptive measures during the course of this study. If the patient was male, they refused to use adequate contraception or sperm donation during the study period and for 3 months after the last study of lymphoma-related chemotherapy drugs
Allergic to any medication in the program
Grade III or IV heart disease based on the New York Heart Association (NYHA) score
Major active bleeding of internal organs (including gastrointestinal bleeding, alveolar bleeding, intracranial bleeding, etc.)
Acute pancreatitis
People infected with HIV (HIV antibody positive)
HBV DNA copy number is >10^4/ml in patients with acute or chronic active hepatitis B, and HBV DNA copy number is >10^4/ml in patients with acute or chronic active hepatitis C (HCV antibody positive, HCV RNA negative acceptable)
Participate in other clinical investigators
The investigators identified patients who were not eligible for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note